Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 19;14(7):693.
doi: 10.3390/ph14070693.

Synthesis and Human Carbonic Anhydrase I, II, IX, and XII Inhibition Studies of Sulphonamides Incorporating Mono-, Bi- and Tricyclic Imide Moieties

Affiliations

Synthesis and Human Carbonic Anhydrase I, II, IX, and XII Inhibition Studies of Sulphonamides Incorporating Mono-, Bi- and Tricyclic Imide Moieties

Kalyan K Sethi et al. Pharmaceuticals (Basel). .

Abstract

New derivatives were synthesised by reaction of amino-containing aromatic sulphonamides with mono-, bi-, and tricyclic anhydrides. These sulphonamides were investigated as human carbonic anhydrases (hCAs, EC 4.2.1.1) I, II, IX, and XII inhibitors. hCA I was inhibited with inhibition constants (Kis) ranging from 49 to >10,000 nM. The physiologically dominant hCA II was significantly inhibited by most of the sulphonamide with the Kis ranging between 2.4 and 4515 nM. hCA IX and hCA XII were inhibited by these sulphonamides in the range of 9.7 to 7766 nM and 14 to 316 nM, respectively. The structure-activity relationships (SAR) are rationalised with the help of molecular docking studies.

Keywords: SAR; anhydride; benzenesulphonamide; docking; human carbonic anhydrase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
3D multiple superpositions of four α-hCAs crystal structures (high sequence alignment homology) [23]. The multiple superpositions involved the following crystal structures: 1AZM (hCA I); 1ZFQ (CA II); 3IAI (CA IX); and 1JD0 (CA XII) with the Zn ion shown as red sphere, and its coordinating residues His 94, His 96, and His 119 shown in pink. The protein backbone is shown in green [1,20].
Figure 2
Figure 2
Resulting designed structural element (HIT) as hCA inhibitor from the outcome of ligand and structure-based drug design (CoMFA, CoMSIA, and pharmacophore modelling) [21].
Scheme 1
Scheme 1
Synthesis of sulphonamide derivatives 1–13 incorporating phthalic anhydride moiety to different benzene sulphonamides [22,23,24,29]. n = 0 (1, 6, 9, 10, 11, 12, and 13); n = 1 (7); n = 2 (2, 8). -(CH2)n = para for 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, and 13; -(CH2)n = meta for 9; -(CH2)n = ortho for 10 in the benzene ring. X = F (5, 11); X = Cl (3, 12); X = Br (4, 13); Z = F (5) in the benzene ring of anhydride. i = glacial acetic acid; ii = stirring with heating.
Figure 3
Figure 3
The proposed steps of the reaction mechanism.
Figure 4
Figure 4
Protein ligand interactions in the 3IAI active site. (a) AAZ coordinates to the zinc ion and formed H-bond with THR 199, THR 200, and two water molecules; (b) Compound 1, the deprotonate sulphonamide binds to the zinc ion and forms H-bonds with HIS 64 (1.87 Å), and THR 199 (2.156 Å).

Similar articles

References

    1. Alterio V., Di Fiore A., D’Ambrosio K., Supuran C.T., De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem. Rev. 2012;112:4421–4468. doi: 10.1021/cr200176r. - DOI - PubMed
    1. Supuran C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008;7:168–181. doi: 10.1038/nrd2467. - DOI - PubMed
    1. Supuran C.T. How many carbonic anhydrase inhibition mechanisms exist? J. Enzyme Inhib. Med. Chem. 2016;31:345–360. doi: 10.3109/14756366.2015.1122001. - DOI - PubMed
    1. Nocentini A., Supuran C.T. Carbonic anhydrase inhibitors as antitumor/anti- metastatic agents: A patent review (2008–2018) Expert Opin. Ther. Pat. 2018;28:729–740. doi: 10.1080/13543776.2018.1508453. - DOI - PubMed
    1. Supuran C.T. Emerging role of carbonic anhydrase inhibitors. Clin. Sci. 2021;135:1233–1249. doi: 10.1042/CS20210040. - DOI - PubMed

LinkOut - more resources